Results 11 to 20 of about 54,096 (328)
Blood, 2023 Abstract The clinical phenotype of primary and post–polycythemia vera and postessential thrombocythemia myelofibrosis (MF) is dominated by splenomegaly, symptomatology, a variety of blood cell alterations, and a tendency to develop vascular complications and blast phase.
Francesco Passamonti, Barbara Mora
openaire +3 more sources
The Journal of Clinical Investigation, 2022 Myeloproliferative neoplasms (MPNs) are associated with significant alterations in the bone marrow microenvironment that include decreased expression of key niche factors and myelofibrosis. Here, we explored the contribution of TGF-β to these alterations
Juo-Chin Yao +8 more
doaj +2 more sources
Osteolytic lesions in myelofibrosis [PDF]
Clinical Case Reports, 2021 AbstractBony pain in patients with a history of myelofibrosis warrants further investigation. Although skeletal involvement in myelofibrosis is more commonly osteosclerosis or periostitis, it can also cause osteolytic lesions.
Isla Johnson, Hassan Alkhateeb
openaire +4 more sources
Blood Advances, 2020 Abstract Following the discovery of the JAK2V617F mutation in myeloproliferative neoplasms in 2005, fedratinib was developed as a small molecular inhibitor of JAK2. It was optimized to yield low-nanomolar activity against JAK2 (50% inhibitory concentration = 3 nM) and was identified to be selective for JAK2 relative to other JAK family ...
Ruben A. Mesa +5 more
openaire +4 more sources
The odyssey of pacritinib in myelofibrosis
Blood Advances, 2022 Abstract Myelofibrosis (MF) can present with symptomatic splenomegaly and/or cytopenias including thrombocytopenia. Disease-related thrombocytopenia is a poor prognostic factor with a median overall survival of less than 2 years. Currently approved JAK1/2 inhibitors have not been evaluated in patients with platelets ≤ 50 × 109/L and in ...
Sangeetha Venugopal, John Mascarenhas
openaire +3 more sources
Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia [PDF]
Revista Brasileira de Hematologia e Hemoterapia, 2011 BACKGROUND: The detection of molecular and cytogenetic alterations is important for the diagnosis, prognosis and classification of myeloproliferative neoplasms. OBJECTIVE: The aim of this study was to detect the following mutations: JAK2 V617F, JAK2 exon
Cerutti, Janete Maria +5 more
core +5 more sources
Successful Management of Lupus‐Associated Autoimmune Myelofibrosis with Tofacitinib: A Case Report [PDF]
ACR Open RheumatologyWe report a case of a 34‐year‐old woman with systemic lupus erythematosus (SLE) who developed thrombocytopenia and was diagnosed with lupus‐associated autoimmune myelofibrosis.
Hamidreza Soltani, Ali Dehghan
doaj +2 more sources
Acute massive myelofibrosis with acutelymphoblastic leukemia [PDF]
Turkish Journal of Hematology, 2009 Acute myelofibrosis is characterized by pancytopenia of sudden onset, megakaryocytic hyperplasia, extensive bone marrow fibrosis, and the absence of organomegaly. Acute myelofibrosis in patients with acute lymphoblastic leukemia is extremely rare.
Barış Malbora +5 more
core +2 more sources
Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management
American journal of hematology/oncology, 2023 Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell‐derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticulin ...
A. Tefferi
semanticscholar +1 more source
Journal of Clinical Oncology, 2023 PURPOSE Standard therapy for myelofibrosis comprises Janus kinase inhibitors (JAKis), yet spleen response rates of 30%-40%, high discontinuation rates, and a lack of disease modification highlight an unmet need.
J. Mascarenhas +23 more
semanticscholar +1 more source